Tim Anderson
Tim Anderson
Timothy Devon Andersonis an American professional baseball shortstop for the Chicago White Sox of Major League Baseball. Anderson played college baseball at East Central Community College, and was selected in the first round of the 2013 MLB draft by the White Sox. He made his MLB debut on June 10, 2016...
ProfessionBaseball Player
Date of Birth23 June 1993
beat company earnings key sale several
While the company beat earnings (expectations), sale for several key franchises lagged our estimates.
ahead company consensus expect good guidance negative
We expect the company to put up a good show, give guidance that is ahead of consensus and not have any significant negative surprises.
above although below company earnings expenses growth historical income interest lighter met quality rate sales tax weaker
Although the company met consensus, the quality of earnings was poor, in our view, because sales growth was weaker than we forecast, expenses were lighter than expected, interest income was above guidance, and the tax rate was significantly below historical levels.
acting companies company couple facing happen happens ironically run supposed turnaround
The company's not going out of business, but ironically it's acting like a cyclical, which drug companies aren't supposed to do. The turnaround may not happen for a couple of years, but it's a well run company that just happens to be facing a lot of problems.
bristol company concern decent drop far next patent shoe
The concern is that Bristol could be the next shoe to drop as far as patent expiration and reining in the numbers, ... But the company has a pretty decent late-stage pipeline.
fda follow full
I think that the FDA will follow up with full approval,
case cold hope
Our hope (in this case) is we will get a cold hit, ... It's important that we put this case to rest.
hoping
I'm hoping they'll come out with more than they did on Jan. 20, when they weren't as forthcoming as I was hoping.
earnings growth guidance revenue seems tells
Merck tells an interesting story, yet the five-year revenue and earnings growth guidance seems far-fetched.
cancer data revenue translate
While the breast cancer data is interesting, we don't think it will translate into a significant new revenue stream.
good growth pivotal
The real pivotal one will be Claritin, ... You could see some very good growth there.
benefits move proof pudding
The proof of the pudding will be what are the benefits at the checkpoint. Will you be able to move through faster? If so, I think this will be a very well-received program.
amount buy figured growth
With their amount of cash, if Pfizer couldn't get growth organically, I figured they would buy their growth through more acquisitions.
clubhouse hole last settle
We wanted to try to get all the way to the clubhouse and settle it on the last hole and we got there.